Recruiting

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

ClinicalTrials.gov IDNCT07228221

PhasePHASE4

Enrollment20

SponsorJonathon Myers

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma

About this study

Interventions

Device: iStent infinite trabecular micro-bypass system model iS3 — surgery perfomed using the iStent infinite trabecular micro-bypass system model iS3
Drug: iDose TR (Travoprost intracameral Implant) 75mcg — surgery performed using the iDose TR (Travoprost intracameral Implant) 75mcg

Primary outcomes

IOP reduction from baseline (Diurnal IOP reduction from baseline at 12 months)

Eligibility information

Inclusion Criteria: * Moderate to severe open angle glaucoma (including POAG, PG, and PXG) * Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9 * Visual acuity HM or better * VF MD -6dB or worse * Failed medical therapy and/or laser treatment * Incisional glaucoma surgery contemplated as next intervention * Phakic or pseudophakic Exclusion Criteria: * Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma * Previous incisional glaucoma surgery * ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days * Active ocular inflammation or edema, clinically significant corneal dystrophy * Corneal or other pathology preventing accurate Goldmann applanation tonometry

Study locations

Wills Eye Hosital Glaucoma Dept., Philadelphia, Pennsylvania 19107 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.